American Esoteric Laboratories (AEL) is a laboratory providing diagnostic testing services. It is self-described as being accredited by the College of American Pathologists and licensed by the State of Tennessee.

American Esoteric Laboratories (AEL)

Genomic Health, Inc. was a company focusing on genetic research specifically in cancer detection, based out of Redwood City, California. The company developed Oncotype DX, a genomic assay that quantified the likelihood of breast cancer recurrence.

Randy Scott

Genomic Health, Inc.

ICPD is a laboratory services company that specializes in determining optimal dosing for antimicrobial drugs through research and testing to reduce the risk of developing antimicrobial resistance.

ICPD

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

Metric
Company Name	American Esoteric Laboratories (AEL)	Genomic Health, Inc.	ICPD	Myriad Genetics, Inc.
Symbol				MYGN
MSH ID	COM:AEL	COM:GENOMICHEALTH	COM:ICPD	COM:MYRIAD
Market	PRIVATE	PRIVATE	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Healthcare	Healthcare & Health Services	Healthcare
Industry	Medical Diagnostics	Genomics	Laboratory Services & Drug Development	Medical - Diagnostics & Research
Country	US	US	US	US
Stage
Employee Count		336		2.70K
Website	ael.com	genomichealth.com	icpd.com	myriad.com
LinkedIn		genomic-health
Founders

Metric
Market Cap			2.28B
Enterprise Value
Monthly Web Traffic	89	1.51K	208.71K
Web Traffic Growth	1.01	-0.74	0.45
Valuation
Raised Capital			90M

Metric
Revenue				678.40M
Revenue (LTM)
Revenue (NTM)
Gross Profit				476.40M
EBITDA				-67.80M
Operating Income				-123.70M
Net Income				-112M
EPS				-1.39
Diluted EPS				-1.39
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin				0.69
Operating Profit Margin				-0.37
EBITDA Margin				-0.10
Net Profit Margin				-0.37
Return on Equity				-0.25
Return on Assets				-0.15
Return on Capital Employed				-0.18

COM:AEL

American Esoteric Laboratories (AEL)

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio				-6.54
P/B Ratio				2.63
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio				6.58
EV Multiple				-7.65

Metric
Days Sales Outstanding				57.25
Days Payables Outstanding				54.15
Days Inventory Outstanding				79.39
Operating Cycle				191.40
Cash Conversion Cycle				84.17
Asset Turnover				0.64

Metric
Operating Cash Flow				-110.90M
Free Cash Flow				-184.20M
Cash Flow to Debt				-0.11
Operating Cash Flow/Sales				-0.06
Free Cash Flow Yield				-0.08

Metric
Cash & Equivalents				132.10M
Accounts Receivable				3.80M
Inventory				22M
Goodwill				287.40M
Debt to Capitalization				0.23
Debt to Assets				0.18
Current Ratio				1.27
Quick Ratio				1.15

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue				0.05
R&D to Revenue				0.12
SG&A to Revenue				0.94